Analysing the Graft versus host disease in allogenic stem cell transplant patient by adding with or without sitagliptin.
Not Applicable
- Conditions
- Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs
- Registration Number
- CTRI/2021/12/038469
- Lead Sponsor
- Dr Sachin Suresh Jadhav
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
all patients undergoing an allogeneic HSCT in our Department
Exclusion Criteria
None
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of acute GVHD as per National Institutes of Health (NIH) consensus criteriaTimepoint: 5 years
- Secondary Outcome Measures
Name Time Method Chronic GVHD at last follow-up <br/ ><br>Relapse free survival at last follow-up <br/ ><br>Overall survival at last follow-up <br/ ><br>Timepoint: 5 years